Close Menu

Insight Genetics

Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.

The company is developing molecular cancer diagnostics, including a test designed to monitor therapy resistance in non-small cell lung cancer patients.

The deal centers around ALK, a gene involved in signal transduction and a therapeutic target for non-small cell lung cancer.

WaferGen Biosystems said this week that it has appointed Keith Warner as chief operating officer and Michael Henighan as CFO.

Asuragen said this week that it has appointed Matthew McManus as CEO and president.

A team of researchers in Germany has developed a new assay to help determine which non-small cell lung cancers are likely to respond to certain targeted therapies.

NEW YORK (GenomeWeb News) – Insight Genetics is working with Vanderbilt-Ingram Cancer Center to identify genetic markers associated with treatment response for triple-negative breast cancer patients.

NEW YORK (GenomeWeb News) — Insight Genetics said yesterday that it has received a new $1.5 million grant from the National Cancer Institute.

NEW YORK (GenomeWeb News) – In June, Veracyte entered into a loan and security agreement with an unnamed financial institution for term loans of up to $10.0 million in aggregate, the company said in its recent Form 10-Q filed with the US Securities and Exchange Commission.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.